{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670318204529664.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1038/s41598-018-22229-5"}},{"identifier":{"@type":"URI","@value":"https://www.nature.com/articles/s41598-018-22229-5.pdf"}},{"identifier":{"@type":"URI","@value":"https://www.nature.com/articles/s41598-018-22229-5"}},{"identifier":{"@type":"PMID","@value":"29507299"}}],"dc:title":[{"@value":"Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title><jats:p>Clinical and experimental studies have shown that sodium glucose co-transporter 2 inhibitors (SGLT2i) contribute to the prevention of diabetic kidney disease progression. In order to clarify its pharmacological effects on the molecular mechanisms underlying the development of diabetic kidney disease, we administered different doses of the SGLT2i, ipragliflozin, to type 2 diabetic mice. A high-dose ipragliflozin treatment for 8 weeks lowered blood glucose levels and reduced urinary albumin excretion. High- and low-dose ipragliflozin both inhibited renal and glomerular hypertrophy, and reduced NADPH oxidase 4 expression and subsequent oxidative stress. Analysis of glomerular phenotypes using glomeruli isolation demonstrated that ipragliflozin preserved podocyte integrity and reduced oxidative stress. Regarding renal tissue hypoxia, a short-term ipragliflozin treatment improved oxygen tension in the kidney cortex, in which SGLT2 is predominantly expressed. We then administered ipragliflozin to type 1 diabetic mice and found that high- and low-dose ipragliflozin both reduced urinary albumin excretion. In conclusion, we confirmed dose-dependent differences in the effects of ipragliflozin on early diabetic nephropathy <jats:italic>in vivo</jats:italic>. Even low-dose ipragliflozin reduced renal cortical hypoxia and abnormal hemodynamics in early diabetic nephropathy. In addition to these effects, high-dose ipragliflozin exerted renoprotective effects by reducing oxidative stress in tubular epithelia and glomerular podocytes.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670318204529795","@type":"Researcher","foaf:name":[{"@value":"Michitsugu Kamezaki"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318204529798","@type":"Researcher","foaf:name":[{"@value":"Tetsuro Kusaba"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318204529668","@type":"Researcher","foaf:name":[{"@value":"Kazumi Komaki"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318204529796","@type":"Researcher","foaf:name":[{"@value":"Yohei Fushimura"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318204529792","@type":"Researcher","foaf:name":[{"@value":"Noriko Watanabe"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318204529665","@type":"Researcher","foaf:name":[{"@value":"Kisho Ikeda"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318204529802","@type":"Researcher","foaf:name":[{"@value":"Takashi Kitani"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318204529800","@type":"Researcher","foaf:name":[{"@value":"Noriyuki Yamashita"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318204529666","@type":"Researcher","foaf:name":[{"@value":"Masahiro Uehara"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318204529667","@type":"Researcher","foaf:name":[{"@value":"Yuhei Kirita"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318204529793","@type":"Researcher","foaf:name":[{"@value":"Yayoi Shiotsu"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318204529664","@type":"Researcher","foaf:name":[{"@value":"Ryosuke Sakai"}]},{"@id":"https://cir.nii.ac.jp/crid/1420001326213245440","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"70782077"},{"@type":"NRID","@value":"1000070782077"},{"@type":"NRID","@value":"9000363352286"},{"@type":"NRID","@value":"9000022059946"},{"@type":"NRID","@value":"9000375895896"},{"@type":"NRID","@value":"9000345286910"},{"@type":"NRID","@value":"9000403159614"},{"@type":"NRID","@value":"9000389438984"},{"@type":"NRID","@value":"9000398139212"},{"@type":"NRID","@value":"9000019241116"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/ft0720"}],"foaf:name":[{"@value":"Takuya Fukuda"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318204529794","@type":"Researcher","foaf:name":[{"@value":"Masahiro Yamazaki"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318204529797","@type":"Researcher","foaf:name":[{"@value":"Michiaki Fukui"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318204529803","@type":"Researcher","foaf:name":[{"@value":"Satoaki Matoba"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318204529799","@type":"Researcher","foaf:name":[{"@value":"Keiichi Tamagaki"}]}],"publication":{"publicationIdentifier":[{"@type":"EISSN","@value":"20452322"}],"prism:publicationName":[{"@value":"Scientific Reports"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2018-03-05","prism:volume":"8","prism:number":"1","prism:startingPage":"4029"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","dc:rights":["https://creativecommons.org/licenses/by/4.0","https://creativecommons.org/licenses/by/4.0"],"url":[{"@id":"https://www.nature.com/articles/s41598-018-22229-5.pdf"},{"@id":"https://www.nature.com/articles/s41598-018-22229-5"}],"createdAt":"2018-02-27","modifiedAt":"2022-12-21","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Mice","dc:title":"Mice"},{"@id":"https://cir.nii.ac.jp/all?q=Mice,%20Inbred%20BALB%20C","dc:title":"Mice, Inbred BALB C"},{"@id":"https://cir.nii.ac.jp/all?q=Glucosides","dc:title":"Glucosides"},{"@id":"https://cir.nii.ac.jp/all?q=Animals","dc:title":"Animals"},{"@id":"https://cir.nii.ac.jp/all?q=Thiophenes","dc:title":"Thiophenes"},{"@id":"https://cir.nii.ac.jp/all?q=Kidney","dc:title":"Kidney"},{"@id":"https://cir.nii.ac.jp/all?q=Sodium-Glucose%20Transporter%202%20Inhibitors","dc:title":"Sodium-Glucose Transporter 2 Inhibitors"},{"@id":"https://cir.nii.ac.jp/all?q=Article","dc:title":"Article"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050566774879454336","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Sodium Glucose Co-Transporter 2 Inhibitor Ameliorates Autophagic Flux Impairment on Renal Proximal Tubular Cells in Obesity Mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1360013168809386880","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Vaccination Against Receptor for Advanced Glycation End Products Attenuates the Progression of Diabetic Kidney Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360013168833264896","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617529577344","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Mitochondrial Dysfunction in Kidney Disease and Uremic Sarcopenia"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294643826775680","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Direct evidence of proximal tubular proliferation in early diabetic nephropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294643842437248","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Sodium–glucose cotransporter 2 inhibitors in type 2 diabetes patients with renal function impairment slow the annual renal function decline, in a real clinical practice"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298339714969984","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Exploring molecular targets in diabetic kidney disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360568471736176000","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure"}]},{"@id":"https://cir.nii.ac.jp/crid/1360572092695721344","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Update on diagnosis, pathophysiology, and management of diabetic kidney disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360572092765715200","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660705095808","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Canagliflozin, a sodium–glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats"}]},{"@id":"https://cir.nii.ac.jp/crid/1360853567663406336","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861705575182464","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Proximal tubular epithelia-specific transcriptomics of diabetic mice treated with dapagliflozin"}]},{"@id":"https://cir.nii.ac.jp/crid/1390013795251384960","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Nephroprotective Effects of Dapagliflozin in Patients with Type 2 Diabetes"}]},{"@id":"https://cir.nii.ac.jp/crid/1390285300163864960","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes"}]},{"@id":"https://cir.nii.ac.jp/crid/1390856351205548032","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Assessing the Risk Minimization Activity in Risk Management Plans for Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2)"},{"@language":"ja","@value":"ナトリウム・グルコース共輸送体-2（SGLT2）阻害薬に関するリスク管理計画におけるリスク最小化活動の評価"}]},{"@id":"https://cir.nii.ac.jp/crid/1881428067451745280","@type":"Dataset","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Faculty Opinions recommendation of Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production."}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1038/s41598-018-22229-5"},{"@type":"OPENAIRE","@value":"doi_dedup___::584f248137b733d3f1501dbdc7826ef3"},{"@type":"CROSSREF","@value":"10.2337/db20-1257_references_DOI_FVwiraUSjPPnjLnfgG1QatI8Fe8"},{"@type":"CROSSREF","@value":"10.1371/journal.pone.0251135_references_DOI_FVwiraUSjPPnjLnfgG1QatI8Fe8"},{"@type":"CROSSREF","@value":"10.5649/jjphcs.47.464_references_DOI_FVwiraUSjPPnjLnfgG1QatI8Fe8"},{"@type":"CROSSREF","@value":"10.3389/fphys.2020.565023_references_DOI_FVwiraUSjPPnjLnfgG1QatI8Fe8"},{"@type":"CROSSREF","@value":"10.3390/ijms21114054_references_DOI_FVwiraUSjPPnjLnfgG1QatI8Fe8"},{"@type":"CROSSREF","@value":"10.1038/s41598-022-04880-1_references_DOI_FVwiraUSjPPnjLnfgG1QatI8Fe8"},{"@type":"CROSSREF","@value":"10.1111/jdi.13502_references_DOI_FVwiraUSjPPnjLnfgG1QatI8Fe8"},{"@type":"CROSSREF","@value":"10.23876/j.krcp.21.251_references_DOI_FVwiraUSjPPnjLnfgG1QatI8Fe8"},{"@type":"CROSSREF","@value":"10.1177/1753944719894509_references_DOI_FVwiraUSjPPnjLnfgG1QatI8Fe8"},{"@type":"CROSSREF","@value":"10.1111/nep.13860_references_DOI_FVwiraUSjPPnjLnfgG1QatI8Fe8"},{"@type":"CROSSREF","@value":"10.1016/j.cmet.2020.06.020_references_DOI_FVwiraUSjPPnjLnfgG1QatI8Fe8"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.6685-20_references_DOI_FVwiraUSjPPnjLnfgG1QatI8Fe8"},{"@type":"CROSSREF","@value":"10.1111/jdi.13009_references_DOI_FVwiraUSjPPnjLnfgG1QatI8Fe8"},{"@type":"CROSSREF","@value":"10.1007/s13340-020-00444-8_references_DOI_FVwiraUSjPPnjLnfgG1QatI8Fe8"},{"@type":"CROSSREF","@value":"10.1016/j.heliyon.2022.e10615_references_DOI_FVwiraUSjPPnjLnfgG1QatI8Fe8"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.4323-19_references_DOI_FVwiraUSjPPnjLnfgG1QatI8Fe8"}]}